New nasal spray help on the way. Three new nasal therapies for allergic rhinitis appear to bring “new help to the table.”
The first two are propellant-delivered intranasal steroids: QNASL, which delivers beclomethasone; and Zetona, which delivers ciclesonide. The same two medicines have been available in aqueous solution sprays.
The welcome difference is the improved delivery mechanism. Many people find the aqueous forms problematic because they drip down the throat, or they don’t seem to have enough oomph to get up in- to the congested areas. The new propellant devices use a chloroflurocarbon (CFC)-free puff that doesn’t drip and is mighty enough to get past the congestion (and doesn’t damage the ozone layer).
Additionally, a “first” among nasal sprays is now available – a combination spray. Dymista provides a topical steroid (Fluticasone) with a typical antihistamine (Azelastine). There seems to be a symbiotic benefit in combining the two classes of medicine into a single spray, especially in individuals who get an inadequate response to single-entity therapy. For now, the combo comes in an aqueous spray format.